Destiny Pharma Plc has raised £10.4 million from a share placement and open offer which will finance the acquisition of an anti-infective asset shown to have promise in preventing infection from the bacteria Clostridium difficile. The new shares are to be listed on the AIM market of the London Stock Exchange.
